STA Pharmaceutical Co., a WuXi AppTec subsidiary focused on small-molecule pharmaceutical development and manufacturing, has merged with WuXi AppTec’s Pharmaceutical Development Services (PDS) division.

The PDS division offers pre-formulation development, formulation development as well as clinical-trial material manufacturing, packaging, and labeling of oral solid dosage forms, including tablets, capsules, sachets, and oral solutions/suspensions. PDS also has various enabling technology platforms for low-soluble drugs, including spray-dried dispersion, hot-melt extrusion, micro or nano suspensions, and liquid-filled hard gelatin capsules. Two commercial-scale drug-product manufacturing facilities, currently under construction, are expected to become operational later this year and early next year, respectively.

STA, after this merger, will integrated small-molecule active pharmaceutical ingredient and drug product solutions.

Source: WuXi AppTec